Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 5/20 | 0.66 |
| ▸ | GSR | P00390 | 1/20 | 0.50 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.49 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.49 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.45 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | GNPAT | O15228 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | PLG | P00747 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30099610 | 0.99 | FOLH1 (0.68) | FOLH1GSRRIMKLANAALAD2DPP8 | |
| SCHEMBL30099604 | 0.99 | FOLH1 (0.68) | FOLH1GSRRIMKLANAALAD2DPP8 | |
| SCHEMBL31635790 | 0.99 | FOLH1 (0.68) | FOLH1GSRRIMKLANAALAD2DPP8 | |
| SCHEMBL31635788 | 0.99 | FOLH1 (0.68) | FOLH1GSRRIMKLANAALAD2DPP8 | |
| SCHEMBL31635789 | 0.99 | FOLH1 (0.68) | FOLH1GSRRIMKLANAALAD2DPP8 | |
| SCHEMBL31635787 | 0.99 | FOLH1 (0.68) | FOLH1GSRRIMKLANAALAD2DPP8 | |
| SCHEMBL30859428 | 0.99 | FOLH1 (0.68) | FOLH1GSRRIMKLANAALAD2DPP8 | |
| SCHEMBL7166207 | 0.99 | FOLH1 (0.68) | FOLH1GSRRIMKLANAALAD2DPP8 | |
| SCHEMBL29373156 | 0.99 | FOLH1 (0.68) | FOLH1GSRRIMKLANAALAD2DPP8 | |
| SCHEMBL29534232 | 0.99 | FOLH1 (0.68) | FOLH1GSRRIMKLANAALAD2DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11566245-B2 | Oligomeric compounds comprising bicyclic nucleotides and uses thereof | IONIS PHARMACEUTICALS, INC. (US) | 2023-01-31 | — | — | US | claimed |
| EP-4720106-A1 | SECRETIN-DERIVED GLP1R SELECTIVE AGONISTS | Gubra A/S (DK) | 2026-04-08 | — | — | EP | disclosed |
| US-20250376683-A1 | Selective Antisense Compounds and Uses Thereof | IONIS PHARMACEUTICALS, INC. (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250368993-A1 | Oligomeric Compounds Comprising Bicyclic Nucleotides and Uses Thereof | IONIS PHARMACEUTICALS, INC. (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250270554-A1 | Selective Antisense Compounds and Uses Thereof | IONIS PHARMACEUTICALS, INC. (US) | 2025-08-28 | — | — | US | disclosed |
| US-20250066792-A1 | COMPOUNDS AND METHODS FOR MODULATION OF DYSTROPHIA MYOTONICA-PROTEIN KINASE (DMPK) EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2025-02-27 | — | — | US | disclosed |
| WO-2024245946-A1 | SECRETIN-DERIVED GLP1R SELECTIVE AGONISTS | Gubra A/S (DK) | 2024-12-05 | — | — | WO | disclosed |
| US-12152244-B2 | Selective antisense compounds and uses thereof | IONIS PHARMACEUTICALS, INC. (US) | 2024-11-26 | — | — | US | disclosed |
| US-20240368592-A1 | Selective Antisense Compounds and Uses Thereof | IONIS PHARMACEUTICALS, INC. (US) | 2024-11-07 | — | — | US | disclosed |
| US-20240294923-A1 | Selective Antisense Compounds and Uses Thereof | IONIS PHARMACEUTICALS, INC. (US) | 2024-09-05 | — | — | US | disclosed |
| US-20230121967-A1 | Oligomeric Compounds Comprising Bicyclic Nucleotides and Uses Thereof | IONIS PHARMACEUTICALS, INC. (US) | 2023-04-20 | — | — | US | disclosed |
| US-20230113863-A1 | Selective Antisense Compounds and Uses Thereof | IONIS PHARMACEUTICALS, INC. (US) | 2023-04-13 | — | — | US | disclosed |
| EP-4144845-A1 | ANTISENSE COMPOUNDS AND USES THEREOF | Ionis Pharmaceuticals, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| EP-2906255-B1 | ANTISENSE COMPOUNDS AND USES THEREOF | IONIS PHARMACEUTICALS INC (US) | 2023-02-22 | — | — | EP | disclosed |
| US-11566245-B2 | Oligomeric compounds comprising bicyclic nucleotides and uses thereof | IONIS PHARMACEUTICALS, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| US-20230002763-A1 | SELECTIVE ANTISENSE COMPOUNDS AND USES THEREOF | IONIS PHARMACEUTICALS, INC. (US) | 2023-01-05 | — | — | US | disclosed |
| EP-4086347-A2 | SELECTIVE ANTISENSE COMPOUNDS AND USES THEREOF | Ionis Pharmaceuticals, Inc. (US) | 2022-11-09 | — | — | EP | disclosed |
| US-11492615-B2 | Antisense compounds and uses thereof | IONIS PHARMACEUTICALS, INC. (US) | 2022-11-08 | — | — | US | disclosed |
| EP-3995580-A2 | COMPOUNDS AND METHODS FOR MODULATION OF DYSTROPHIA MYOTONICA-PROTEIN KINASE (DMPK) EXPRESSION | Ionis Pharmaceuticals, Inc. (US) | 2022-05-11 | — | — | EP | disclosed |
| EP-3459549-B1 | SELECTIVE ANTISENSE COMPOUNDS AND USES THEREOF | IONIS PHARMACEUTICALS INC (US) | 2022-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11492615-B2 | Antisense compounds and uses thereof | HNRNPUL2, HNRNPA2B1, HNRNPUL1 | FOLH1 1424/4885GSR 2632/4885RIMKLA 3464/4885 |
| US-20230002763-A1 | SELECTIVE ANTISENSE COMPOUNDS AND USES THEREOF | HTT, HNRNPA1, HNRNPUL2 | FOLH1 1538/4885GSR 3392/4885RIMKLA 2662/4885 |
| US-20250270554-A1 | Selective Antisense Compounds and Uses Thereof | HTT, HNRNPA1, HNRNPUL2 | FOLH1 1538/4885GSR 3392/4885RIMKLA 2662/4885 |
| US-12152244-B2 | Selective antisense compounds and uses thereof | HTT, HNRNPA1, HNRNPUL2 | FOLH1 1538/4885GSR 3392/4885RIMKLA 2662/4885 |
| US-20240294923-A1 | Selective Antisense Compounds and Uses Thereof | HNRNPUL2, HNRNPA2B1, HNRNPA1 | FOLH1 1542/4885GSR 3486/4885RIMKLA 3002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.